Cryptococcal infection associated with fludarabine therapy.
Chim
C S
CS
Liang
R
R
Wong
S S
SS
Yuen
K Y
KY
D000970:Antineoplastic Agents / Q000009:adverse effects*; D016516:CD4-CD8 Ratio; D003453:Cryptococcosis / Q000097:blood / Q000139:chemically induced*; D017809:Fatal Outcome; D016469:Fungemia / Q000097:blood / Q000139:chemically induced*; D006801:Humans; D016867:Immunocompromised Host; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000276:immunology; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives*
D000970:Antineoplastic Agents; D014740:Vidarabine; C024352:fludarabine